ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial), an ongoing large‐scale trial conducted by the National Cancer Institute, contains four important components: biomarker analysis for high‐risk resectable NSCLC (A151216), adjuvant nivolumab for NSCLC without EGFR or ALK mutation (EA5142), and adjuvant EGFR (A081105) or ALK (E4512) TKIs for NSCLC with EGFR or ALK mutation.47, 48. Here, ALK is linked to lung cancer.